Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.46 |
| ▸ | ALPL | P05186 | 9/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888926 | 0.79 | HCAR3 (0.51) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL6110152 | 0.77 | HCAR3 (0.45) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL1431995 | 0.77 | ALPL (0.54) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL23930792 | 0.74 | ALPL (0.46) | HCAR3ALPLCA9CA12 | |
| SCHEMBL5599241 | 0.74 | HCAR3 (0.47) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL1092 | 0.74 | HCAR3 (0.54) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL6110120 | 0.73 | HCAR3 (0.42) | HCAR3ALPLCA9CA12TP53 | |
| SCHEMBL5599851 | 0.73 | HCAR2 (0.61) | HCAR3HCAR2 | |
| SCHEMBL16763221 | 0.73 | HCAR3 (0.50) | HCAR3ALPLCA9CA12TP53 | |
| Hydrochloric Acid SCHEMBL31467460 | 0.72 | HCAR3 (0.53) | HCAR3ALPLCA9CA12TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1633351-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005011677-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ACE, AGTR2, ACE2 | HCAR3 150/4885ALPL 982/4885CA9 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.